🇺🇸 Zilovertamab vedotin in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Nausea — 2 reports (14.29%)
  2. Product Use Issue — 2 reports (14.29%)
  3. Respiratory Failure — 2 reports (14.29%)
  4. Sepsis — 2 reports (14.29%)
  5. Anaemia — 1 report (7.14%)
  6. Chronic Lymphocytic Leukaemia Transformation — 1 report (7.14%)
  7. Diarrhoea — 1 report (7.14%)
  8. Febrile Neutropenia — 1 report (7.14%)
  9. Fungal Infection — 1 report (7.14%)
  10. Neutropenia — 1 report (7.14%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Zilovertamab vedotin approved in United States?

Zilovertamab vedotin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Zilovertamab vedotin in United States?

Merck Sharp & Dohme LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.